Market Overview

Synthace Appoints Susan Shiff, PhD, MBA, to Board of Directors

Share:

Pharma industry veteran's data expertise will support Synthace's
commercial expansion of its computer-aided biology platform

Synthace
Ltd.,
the company behind the leading cloud software platform for
automating and improving the success rate of biological research and
development today announced the appointment of Susan Shiff Ph.D., MBA,
to its board of directors.

Susan has over 20 years' experience in major pharmaceutical companies
helping them to collect and use better data to make decisions that
improve business impact. Since 2014 Susan has served as SVP, and Head of
the Centre for Observational and Real-World Evidence at MSD (known as
Merck & Co., Inc., Kenilworth, NJ, USA, in the United States and
Canada). Prior to that, she has held senior positions in similar roles
at Teva, Pfizer, Roche, and Johnson and Johnson.

Susan was selected as one of 15
Fierce Women in Biopharma 2016
, which honours women who are standing
out in the biopharma industry. Additionally, she was named as one of the most
inspiring women in the pharmaceutical industry, 2017.

The appointment of Susan comes as the pharmaceutical industry actively
seeks to combine automation and AI to enable the development of
increasingly complex new therapies.

"This is an exciting time to join the Synthace Board. The flexibility
and power that the Company's software brings to lab automation means the
quality of experimental data and the resulting AI derived insights are
set to improve dramatically" said Dr. Shiff. "I am delighted to be
joining such a dynamic team who are committed to solving the
reproducibility crisis that has long plagued biological research."

"Dr. Shiff's deep understanding of the collection and use of data in
decision making across the many facets of the global pharmaceutical
industry will be invaluable as we transition into a major enterprise
software company, said Dr. Tim Fell, CEO, Synthace. "We are delighted to
have such a highly experienced and well-respected industry leader join
our Board to help us guide the Company's evolution and expansion."

-ENDS-

Tweet this: News! @Synthace welcomes Susan Shiff to its Board of
Directors #UKTech #BioTech #Pharma #WomeninTech https://bit.ly/2LRvAQG

Follow Synthace

Synthace
Blog

Join
the Twitter Conversation

Join
us on LinkedIn

About Synthace

Based in London, Synthace is developing Antha, a language and software
platform specifically for biology that lets researchers aim higher and
achieve better results, faster. Antha is designed to make reproducible
and scalable workflows that can be readily edited and shared, and easily
automated on labs' existing equipment. With customers across pharma,
agritech and industrial biotechnology Synthace has been recognised by
the World Economic Forum as a Technology Pioneer that is helping shape
the Fourth Industrial Revolution – a technological revolution that will
fundamentally alter the way we live, work and relate to one another. For
more information, visit: www.synthace.com.

View Comments and Join the Discussion!